Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia. Issue 16 (29th April 2015)
- Record Type:
- Journal Article
- Title:
- Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia. Issue 16 (29th April 2015)
- Main Title:
- Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia
- Authors:
- El‐Jawahri, Areej R.
Abel, Gregory A.
Steensma, David P.
LeBlanc, Thomas W.
Fathi, Amir T.
Graubert, Timothy A.
DeAngelo, Daniel J.
Wadleigh, Martha
Ballen, Karen K.
Foster, Julia E.
Attar, Eyal C.
Amrein, Philip C.
Brunner, Andrew M.
Stone, Richard M.
Temel, Jennifer S. - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29430-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Health care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied.</p> </sec> <sec id="cncr29430-sec-0002" sec-type="section"> <title>METHODS</title> <p>We conducted a retrospective analysis of 330 consecutive older patients who were diagnosed with AML between May 1, 2005 and December 23, 2011, at 2 hospitals in Boston to examine their health care utilization and end‐of‐life care. Using multivariable logistic and linear regression models adjusting for covariates, we also compared health care utilization between patients who received intensive induction chemotherapy (n = 197; cytarabine/ anthracycline combination) versus nonintensive chemotherapy (n = 133; single‐agent therapy).</p> </sec> <sec id="cncr29430-sec-0003" sec-type="section"> <title>RESULTS</title> <p>The median number of hospitalizations for the entire cohort was 4.2 (range, 1‐18 hospitalizations). Patients who died spent a mean of 28.3% of their life after diagnosis in the hospital and 13.8% of their life attending outpatient clinic appointments. Although the majority of patients (87.9%) died during the 2‐year follow‐up period, a minority received palliative care (16.2%) or hospice (23.1%) services. Within 30 days of death, 84.5% of patients were hospitalized, and 61% died in the hospital. Among the<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29430-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Health care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied.</p> </sec> <sec id="cncr29430-sec-0002" sec-type="section"> <title>METHODS</title> <p>We conducted a retrospective analysis of 330 consecutive older patients who were diagnosed with AML between May 1, 2005 and December 23, 2011, at 2 hospitals in Boston to examine their health care utilization and end‐of‐life care. Using multivariable logistic and linear regression models adjusting for covariates, we also compared health care utilization between patients who received intensive induction chemotherapy (n = 197; cytarabine/ anthracycline combination) versus nonintensive chemotherapy (n = 133; single‐agent therapy).</p> </sec> <sec id="cncr29430-sec-0003" sec-type="section"> <title>RESULTS</title> <p>The median number of hospitalizations for the entire cohort was 4.2 (range, 1‐18 hospitalizations). Patients who died spent a mean of 28.3% of their life after diagnosis in the hospital and 13.8% of their life attending outpatient clinic appointments. Although the majority of patients (87.9%) died during the 2‐year follow‐up period, a minority received palliative care (16.2%) or hospice (23.1%) services. Within 30 days of death, 84.5% of patients were hospitalized, and 61% died in the hospital. Among the patients who died, those who received intensive induction therapy (vs nonintensive therapy) spent 30% more of their life after diagnosis in the hospital (<italic>P</italic> &lt; .0001) and were less likely to receive hospice services (odds ratio, 0.45; <italic>P</italic> = .05).</p> </sec> <sec id="cncr29430-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>The current findings highlight the intensity of health care utilization among older patients with AML, regardless of treatment modality. Despite the poor prognosis, palliative care and hospice services are rarely used. Future work should study novel health care delivery models to optimize care throughout the course of illness and at the end of life. <bold><italic>Cancer</italic> 2015;121:2840‐2848.</bold> © <italic>2015 American Cancer Society</italic></p> </sec> </abstract> … (more)
- Is Part Of:
- Cancer. Volume 121:Issue 16(2015)
- Journal:
- Cancer
- Issue:
- Volume 121:Issue 16(2015)
- Issue Display:
- Volume 121, Issue 16 (2015)
- Year:
- 2015
- Volume:
- 121
- Issue:
- 16
- Issue Sort Value:
- 2015-0121-0016-0000
- Page Start:
- 2840
- Page End:
- 2848
- Publication Date:
- 2015-04-29
- Subjects:
- Cancer -- Periodicals
Cancer -- Cytopathology -- Periodicals
616.99405 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cncr.29430 ↗
- Languages:
- English
- ISSNs:
- 0008-543X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.450000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4072.xml